Temozolomide for Brain Tumors

Last Modified: September 24, 2006

Share article


Dear OncoLink "Ask The Experts,"

My friend has very recently been diagnosed with a grade 4 Glioblastoma. She begins radiation therapy (XRT) next week on a palliative basis. Is there any evidence that the use of the drug Temodar (temozolomide) would improve her survival, and if there is, what would a course of this drug entail?


Robert Lustig MD FACR, Clinical Associate Professor, Department of Radiation Oncology, University of Pennsylvania, responds:

Glioblastoma multiforme is a grade IV (out of IV) astrocytoma, which is a very aggressive primary cancer of the brain. The drug temozolomide, or Temodar, is now part of the standard of care in glioblastoma treatment. It is given daily at a dose of 75 mg/m 2 (based on body size) starting on day one of radiation and continuing until the last day. After a one month rest, temozolomide is then restarted at a higher dose for 5 days, followed by a 3-week rest, and continued in this way until disease progression.

Brain Tumor Combination Treatment Improves Survival

Mar 29, 2015 - Combined postoperative treatment of glioblastoma patients with radiation and temozolomide improves five-year survival over radiation alone, though most patients still eventually die of the disease, according to an article published online Mar. 9 in The Lancet Oncology.

I Wish You Knew

How cancer patients have changed my life

View More

Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More